{"content":"<li class=\"n-box-item date-title\" data-end=\"1495511999\" data-start=\"1495425600\" data-txt=\"Monday, December 23, 2019\">Monday, May 22, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3269166\" data-ts=\"1495492626\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269166-optical-network-names-rebound-analysts-see-china-recovery\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Optical network names rebound as analysts see China recovery</a></h4><ul>   <li>Optical network stocks -- moving up and down of late with <a href=\"https://seekingalpha.com/news/3257999-fiber-optics-part-makers-take-hit-amid-concerns-china-slowdown\" target=\"_blank\">any news on demand from China</a> -- got a lift today as analysts pointed to a likely recovery there.</li>    <li>Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) <font color='green'>rose 12.1%</font> to a new all-time high. Other related names: Oclaro (NASDAQ:<a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a>) <font color='green'>+10.2%</font>; Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>) <font color='green'>+10.2%</font>; Lumentum (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>) <font color='green'>+7.5%</font>; NeoPhotonics (NYSE:<a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a>) <font color='green'>+10%</font>; Emcore (NASDAQ:<a href='https://seekingalpha.com/symbol/EMKR' title='EMCORE Corporation'>EMKR</a>) <font color='green'>+3%</font>. Macom Technology (NASDAQ:<a href='https://seekingalpha.com/symbol/MTSI' title='MACOM Technology Solutions Holdings, Inc.'>MTSI</a>), with Optoelectronics and Photonic Solutions units among its businesses, closed <font color='green'>up 8.3%</font>.</li>    <li>Needham launched Applied Opto at Strong Buy, expecting ASPs and margins to go up as the company's product mix moves toward 25G/100G products from the existing 10G/40G line. Applied is the market share leader and the low-cost supplier, Needham says.</li>    <li>Meanwhile, Jefferies <a href=\"http://thefly.com/landingPageNews.php?id=2556006&amp;headline=OCLR;LITE;FNSR;NPTN;AAOI;CHL;CHA;CHU-Optical-network-names-surge-as-China-demand-seen-recovering\" target=\"_blank\">reiterated Buys on Oclaro, Lumentum and Finisar</a>, pointing to China Mobile's vendor selection for its packet transport network mostly going to ZTE (to which Oclaro has 10% revenue exposure).</li>    <li>China Telecom and China Unicom will follow up with their tenders later this year, and Jefferies' James Kisner expects they will reinforce what looks like a return to spending in the sector.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269166\" data-linked=\"Optical network names rebound as analysts see China recovery\" data-tweet=\"$AAOI $AAOI $OCLR - Optical network names rebound as analysts see China recovery https://seekingalpha.com/news/3269166-optical-network-names-rebound-analysts-see-china-recovery?source=tweet\" data-url=\"https://seekingalpha.com/news/3269166-optical-network-names-rebound-analysts-see-china-recovery\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269164\" data-ts=\"1495490909\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TTWO\" target=\"_blank\">TTWO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269164-take-twominus-9-on-red-dead-redemption-2-delay\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Take-Two -9% on &#39;Red Dead Redemption 2&#39; delay</a></h4><ul>   <li>Take-Two Interactive (NASDAQ:<a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a>) has tumbled and is <font color='red'>down 9%</font> now after hours after news that highly anticipated game sequel <i>Red Dead Redemption 2</i> is being <a href=\"http://www.rockstargames.com/newswire/article/60210/Red-Dead-Redemption-2-Is-Now-Coming-Spring-2018\" target=\"_blank\">delayed to spring 2018</a>.</li>    <li>\"We are very sorry for any disappointment this delay causes, but we are firm believers in delivering a game only when it is ready,\" studio Rockstar Games says in a release where it teases new screenshots. The company promises more details on the game this summer.</li>    <li>News of the creation of the game -- a sequel to the follow-up to <i>Red Dead Revolver</i> -- <a href=\"https://seekingalpha.com/news/3214387-take-two-plus-5_7-percent-fans-see-confirmation-red-dead-sequel\" target=\"_blank\">spurred gains in the stock</a> last October. The original <i>Red Dead Redemption</i> shipped more than 14M units.</li>    <li>But the latest sequel had been set to come out in fall 2017, in time for the holiday season.</li>    <li>The company is set to report quarterly earnings before the opening bell tomorrow.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3269164\" data-linked=\"Take-Two -9% on &#39;Red Dead Redemption 2&#39; delay\" data-tweet=\"$TTWO - Take-Two -9% on &#39;Red Dead Redemption 2&#39; delay https://seekingalpha.com/news/3269164-take-twominus-9-on-red-dead-redemption-2-delay?source=tweet\" data-url=\"https://seekingalpha.com/news/3269164-take-twominus-9-on-red-dead-redemption-2-delay\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269159\" data-ts=\"1495490318\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOS\" target=\"_blank\">KOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269159-kosmos-energy-shareholders-launch-40m-share-secondary-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kosmos Energy shareholders launch 40M-share secondary offering</a></h4><ul><li>Kosmos Energy (NYSE:<a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy'>KOS</a>) <font color='red'>-3.8%</font>&nbsp;AH after announcing a 40M-share <a href=\"https://seekingalpha.com/pr/16840379-kosmos-energy-announces-secondary-public-offering-common-shares\" target=\"_blank\">secondary offering</a> by investment funds associated with Blackstone and Warburg Pincus; the selling stockholders will received all proceeds from the offering.</li><li>Upon completion of the offering, one of the directors nominated by Blackstone is expected to resign from the KOS board, and the  P-E firm will have the right to nominate only one designee to  the KOS board.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269159\" data-linked=\"Kosmos Energy shareholders launch 40M-share secondary offering\" data-tweet=\"$KOS - Kosmos Energy shareholders launch 40M-share secondary offering https://seekingalpha.com/news/3269159-kosmos-energy-shareholders-launch-40m-share-secondary-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3269159-kosmos-energy-shareholders-launch-40m-share-secondary-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:58 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269155\" data-ts=\"1495488969\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269155-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies Inc.'>A</a> <font color='green'>+3.9%</font>. <a href='https://seekingalpha.com/symbol/SQM' title='Chemical & Mining Co. of Chile Inc.'>SQM</a> <font color='green'>+3.3%</font>. <a href='https://seekingalpha.com/symbol/PRAA' title='PRA Group, Inc.'>PRAA</a> <font color='green'>+2.7%</font>. <a href='https://seekingalpha.com/symbol/TPH' title='TRI Pointe Group, Inc.'>TPH</a> <font color='green'>+2.2%</font>. <a href='https://seekingalpha.com/symbol/AT' title='Atlantic Power Corporation'>AT</a> <font color='green'>+2.1%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/TTWO' title='Take-Two Interactive Software, Inc.'>TTWO</a> <font color='red'>-9.3%</font>. <a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='red'>-4.6%</font>. <a href='https://seekingalpha.com/symbol/TCS' title='The Container Store Group, Inc.'>TCS</a> <font color='red'>-3.3%</font>. <a href='https://seekingalpha.com/symbol/CLB' title='Core Laboratories'>CLB</a> <font color='red'>-3.3%</font>. <a href='https://seekingalpha.com/symbol/AGTC' title='Applied Genetic Technologies Corporation'>AGTC</a> <font color='red'>-2.8%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269155\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$A $SQM $PRAA - After Hours Gainers / Losers https://seekingalpha.com/news/3269155-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3269155-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269151\" data-ts=\"1495487514\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/H\" target=\"_blank\">H</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269151-hyatt-slides-goldman-funds-to-sell-4m-share-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Hyatt slides as Goldman funds to sell 4M-share stake</a></h4><ul>     <li>Hyatt Hotels (NYSE:<a href='https://seekingalpha.com/symbol/H' title='Hyatt Hotels Corporation'>H</a>) <font color='red'>-2.4%</font>&nbsp;AH after announcing a 4M-share <a href=\"https://seekingalpha.com/pr/16840390-hyatt-announces-secondary-offering-4000-000-shares-class-common-stock\" target=\"_blank\">secondary offering</a> by  investment funds associated with Goldman Sachs; the selling stockholders will receive all proceeds from the offering.</li>     <li>H has 125.5M shares outstanding.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269151\" data-linked=\"Hyatt slides as Goldman funds to sell 4M-share stake\" data-tweet=\"$H - Hyatt slides as Goldman funds to sell 4M-share stake https://seekingalpha.com/news/3269151-hyatt-slides-goldman-funds-to-sell-4m-share-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3269151-hyatt-slides-goldman-funds-to-sell-4m-share-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269124\" data-ts=\"1495484764\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/A\" target=\"_blank\">A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269124-agilent-fiscal-q2-top-line-up-8-earnings-up-80-cash-flow-up-1-shares-ahead-4-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agilent fiscal Q2 top line up 8%, earnings up 80%, cash flow up 1%; shares ahead 4% after hours</a></h4><ul><li>Agilent (NYSE:<a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies Inc.'>A</a>) <a href=\"https://seekingalpha.com/pr/16840292-agilent-technologies-reports-second-quarter-fiscal-year-2017-financial-results\" target=\"_blank\">fiscal Q2 results</a> ($M): Total Revenues: 1,102 (+8.1%), Life Sciences &amp; Applied Markets: 523 (+5.7%); Diagnostics &amp; Genomics Group: 201 (+12.9%); Agilent CrossLab: 378 (+9.2%).</li><li>Net Income: 164 (+80.2%); Non-GAAP Net Income: 187 (+29.0%); EPS: 0.50 (+78.6%); Non-GAAP EPS: 0.58 (+31.8%); CF Ops: 257 (+1.2%).</li><li>Results driven by strong demand in Chemical and Energy business and strong growth in Pharma and in Europe.</li><li>Shares are up&nbsp;<font color='green'>4%</font>&nbsp;after hours on increased volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269124\" data-linked=\"Agilent fiscal Q2 top line up 8%, earnings up 80%, cash flow up 1%; shares ahead 4% after hours\" data-tweet=\"$A - Agilent fiscal Q2 top line up 8%, earnings up 80%, cash flow up 1%; shares ahead 4% after hours https://seekingalpha.com/news/3269124-agilent-fiscal-q2-top-line-up-8-earnings-up-80-cash-flow-up-1-shares-ahead-4-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3269124-agilent-fiscal-q2-top-line-up-8-earnings-up-80-cash-flow-up-1-shares-ahead-4-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:26 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269123\" data-ts=\"1495484615\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SNCR\" target=\"_blank\">SNCR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269123-synchronossminus-5_3-after-and-t-deals-end-prompts-cs-downgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Synchronoss -5.3% after AT&amp;T deal&#39;s end prompts CS downgrade</a></h4><ul>     <li>Synchronoss (NASDAQ:<a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a>) <font color='red'>slipped 5.3%</font> today to just 10% above its 52-week low, following a downgrade to Underperform at Credit Suisse based on the end of a deal with AT&amp;T.</li>     <li>The telecom giant is ending its \"Locker\" personal cloud offering, which was powered by Synchronoss -- and while revenue wasn't heavy today, it was expected to be <a href=\"http://thefly.com/landingPageNews.php?id=2555949&amp;headline=SNCR;T;VZ-Analyst-says-sell-Synchronoss-after-ATT-cancels-deal\" target=\"_blank\">\"more meaningful over time,\"</a> says analyst Michael Nemeroff.</li>     <li>Aside from that, the deal cancellation increases the risk that Verizon could alter its cloud deal with Synchronoss in turn, he says. (H/T: The Fly)</li>     <li>The company last week said it was <a href=\"https://seekingalpha.com/pr/16832864-synchronoss-delays-filing-first-quarter-2017-earnings-filing-form-10-q\" target=\"_blank\">delaying its planned release</a> of quarterly earnings to provide more time to comply with internal controls and procedures, and to review aspects of its financials. It \"doesn't expect the delay will be protracted.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269123\" data-linked=\"Synchronoss -5.3% after AT&amp;T deal&#39;s end prompts CS downgrade\" data-tweet=\"$SNCR - Synchronoss -5.3% after AT&amp;T deal&#39;s end prompts CS downgrade https://seekingalpha.com/news/3269123-synchronossminus-5_3-after-and-t-deals-end-prompts-cs-downgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3269123-synchronossminus-5_3-after-and-t-deals-end-prompts-cs-downgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:23 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269111\" data-ts=\"1495483812\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GLYC\" target=\"_blank\">GLYC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269111-glycomimetics-readies-6m-share-stock-offering-shares-off-19-after-hours\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GlycoMimetics readies 6M-share stock offering; shares off 19% after hours</a></h4><ul><li>GlycoMimetics (NASDAQ:<a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a>) slumps&nbsp;<font color='red'>19%</font>&nbsp;after hours on increased volume in response to its <a href=\"https://seekingalpha.com/pr/16840275-glycomimetics-announces-proposed-public-offering-common-stock\" target=\"_blank\">planned public offering</a> of 6M shares of common stock. Price and terms have yet to be announced.</li><li>Net proceeds will fund several clinical trials, R&amp;D, working capital and general corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269111\" data-linked=\"GlycoMimetics readies 6M-share stock offering; shares off 19% after hours\" data-tweet=\"$GLYC - GlycoMimetics readies 6M-share stock offering; shares off 19% after hours https://seekingalpha.com/news/3269111-glycomimetics-readies-6m-share-stock-offering-shares-off-19-after-hours?source=tweet\" data-url=\"https://seekingalpha.com/news/3269111-glycomimetics-readies-6m-share-stock-offering-shares-off-19-after-hours\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:10 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269109\" data-ts=\"1495483565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/A\" target=\"_blank\">A</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269109-agilent-beats-0_10-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Agilent beats by $0.10, beats on revenue</a></h4><ul><li>Agilent (NYSE:<a href='https://seekingalpha.com/symbol/A' title='Agilent Technologies Inc.'>A</a>): Q2 EPS of $0.58 <font color='green'>beats by $0.10</font>.</li><li>Revenue of $1.1B (+7.8% Y/Y) <font color='green'>beats by $50M</font>.</li><li>Shares <font color='green'>+3.2%</font>.</li><li><a href='https://seekingalpha.com/pr/16840292-agilent-technologies-reports-second-quarter-fiscal-year-2017-financial-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3269109\" data-linked=\"Agilent beats by $0.10, beats on revenue\" data-tweet=\"$A - Agilent beats by $0.10, beats on revenue https://seekingalpha.com/news/3269109-agilent-beats-0_10-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3269109-agilent-beats-0_10-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269106\" data-ts=\"1495482746\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SM\" target=\"_blank\">SM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269106-sm-energy-to-record-150m-200m-non-cash-on-pulled-asset-sale\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SM Energy to record $150M-$200M non-cash on pulled asset sale</a></h4><ul>     <li>SM&nbsp;Energy (<a href='https://seekingalpha.com/symbol/SM' title='SM Energy Company'>SM</a> <font color='red'>-4.4%</font>) sinks after <a href=\"https://seekingalpha.com/filing/3560640\" target=\"_blank\">disclosing</a> it expects to record a pre-tax non-cash $150M-$200M impairment charge in Q2 related to a loss on the postponed sale of North Dakota assets.</li>     <li>SM announced <a href=\"https://seekingalpha.com/news/3267751-sm-energy-pulls-planned-sale-north-dakota-assets\" target=\"_blank\">last week</a> that it postponed indefinitely the planned sale of its Divide County, N.D., assets, as valuations in the sales process did not reach its threshold to meaningfully reduce leverage.</li>     <li>SM expects no cash expenditures as a result of the impairment charge.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269106\" data-linked=\"SM Energy to record $150M-$200M non-cash on pulled asset sale\" data-tweet=\"$SM - SM Energy to record $150M-$200M non-cash on pulled asset sale https://seekingalpha.com/news/3269106-sm-energy-to-record-150m-200m-non-cash-on-pulled-asset-sale?source=tweet\" data-url=\"https://seekingalpha.com/news/3269106-sm-energy-to-record-150m-200m-non-cash-on-pulled-asset-sale\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269103\" data-ts=\"1495482311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269103-forbes-herper-says-ad-comm-thumbs-up-on-pumas-neratinib-not-sure-thing-shares-ahead-36\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Forbe&#39;s Herper says Ad Comm thumbs up on Puma&#39;s neratinib not a sure thing; shares ahead 36%</a></h4><ul><li>Puma Biotechnology (<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+36.2%</font>) has been up big all day on more than a 10x surge in volume as investors like what they see in the briefing documents ahead of Wednesday's advisory committee review of neratinib for the treatment of HER2+ breast cancer.</li><li>Forbe's Matthew Herper agrees that the docs \"don't look as bad as bears expected\" but a positive vote is not a slam dunk. There are two significant \"deal-killers\" that the committee will address: the high rate of diarrhea and the number of changes made to the study that affected the statistical validity of the data. Apparently, the results were so concerning that the agency advised the company not to file a new NDA when it approached the regulator about doing so. Mr. Herper says the opinion of statistical expert Ralph D'Agostino will be a major factor.</li><li>Provision Policy analyst Michael McCaughen says the odds of the committee backing approval are a \"coin flip.\"</li><li>Source: The Fly</li><li>Previously: <a href=\"https://seekingalpha.com/news/3269037-briefing-docs-ad-comm-review-pumas-neratinib-shares-52-percent\" target=\"_blank\">Briefing docs out for Ad Comm review of Puma's neratinib; shares up 52%</a> (May 22)</li></ul><div class=\"tiny-share-widget\" data-id=\"3269103\" data-linked=\"Forbe&#39;s Herper says Ad Comm thumbs up on Puma&#39;s neratinib not a sure thing; shares ahead 36%\" data-tweet=\"$PBYI - Forbe&#39;s Herper says Ad Comm thumbs up on Puma&#39;s neratinib not a sure thing; shares ahead 36% https://seekingalpha.com/news/3269103-forbes-herper-says-ad-comm-thumbs-up-on-pumas-neratinib-not-sure-thing-shares-ahead-36?source=tweet\" data-url=\"https://seekingalpha.com/news/3269103-forbes-herper-says-ad-comm-thumbs-up-on-pumas-neratinib-not-sure-thing-shares-ahead-36\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269100\" data-ts=\"1495481310\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FLXN\" target=\"_blank\">FLXN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269100-economic-analysis-shows-cost-effectiveness-of-flexions-zilretta-for-treating-knee\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Economic analysis shows cost effectiveness of Flexion&#39;s Zilretta for treating knee osteoarthritis pain; shares up 9%</a></h4><ul><li>Flexion Therapeutics (<a href='https://seekingalpha.com/symbol/FLXN' title='Flexion Therapeutics, Inc.'>FLXN</a> <font color='green'>+8.5%</font>) is up on below average volume. Earlier today, it <a href=\"https://seekingalpha.com/pr/16839435-flexion-present-new-cost-effectiveness-data-zilretta-fx006-international-society\" target=\"_blank\">announced </a>the results of a health economics analysis of Zilretta (FX006) for the treatment of knee osteoarthritis pain. The results will be presented at the International Society for Pharmacoeconomics and Outcomes Research &#40;ISPOR&#41; 22nd International Meeting in Boston.</li><li>The study was designed to estimate Zilretta's impact on patients' quality of life and it cost effectiveness with other therapies. Based on a cost/treatment of $500, Zilretta had a greater impact on quality-of-life measures that conventional care, diclofenac &#40;NSAID&#41; and HA treatment.</li><li>Treatment with Zilretta also showed cost effectiveness against conventional care and HA treatment, but not quite low as diclofenac.</li><li>The company's U.S. marketing application is currently under FDA review with an action date of October 6.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269100\" data-linked=\"Economic analysis shows cost effectiveness of Flexion&#39;s Zilretta for treating knee osteoarthritis pain; shares up 9%\" data-tweet=\"$FLXN - Economic analysis shows cost effectiveness of Flexion&#39;s Zilretta for treating knee osteoarthritis pain; shares up 9% https://seekingalpha.com/news/3269100-economic-analysis-shows-cost-effectiveness-of-flexions-zilretta-for-treating-knee?source=tweet\" data-url=\"https://seekingalpha.com/news/3269100-economic-analysis-shows-cost-effectiveness-of-flexions-zilretta-for-treating-knee\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:28 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269099\" data-ts=\"1495480699\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VTNR\" target=\"_blank\">VTNR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269099-abu-dhabi-to-sell-group-iii-base-oils-u-s-via-vertex-partnership\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Abu Dhabi to sell Group III base oils into U.S. via Vertex partnership</a></h4><ul>     <li>Vertex Energy (<a href='https://seekingalpha.com/symbol/VTNR' title='Vertex Energy, Inc.'>VTNR</a> <font color='green'>+5.1%</font>) surges after Abu Dhabi National Oil signs an agreement naming VTNR partner company Penthol as the <a href=\"https://seekingalpha.com/pr/16839369-adnoc-signs-exclusive-agreement-penthol-group-iii-base-oil-sales-united-states-america-vertex\" target=\"_blank\">exclusive U.S. seller</a> of its Group III base oils.</li>     <li>ADNOC produces up to 500K metric tons/year of Group III base oils - which are typically used to manufacture high performance engine oils - through its own refinery.</li>     <li>VTNR is Penthol's sole marketing agent in the U.S.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269099\" data-linked=\"Abu Dhabi to sell Group III base oils into U.S. via Vertex partnership\" data-tweet=\"$VTNR - Abu Dhabi to sell Group III base oils into U.S. via Vertex partnership https://seekingalpha.com/news/3269099-abu-dhabi-to-sell-group-iii-base-oils-u-s-via-vertex-partnership?source=tweet\" data-url=\"https://seekingalpha.com/news/3269099-abu-dhabi-to-sell-group-iii-base-oils-u-s-via-vertex-partnership\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:18 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269092\" data-ts=\"1495478893\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269092-technology-top-gainers-losers-of-2-45-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 2:45 pm</a></h4><ul>     <li><b>Gainers:</b> COOL <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/QUIK' title='QuickLogic Corporation'>QUIK</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/IPDN' title='Professional Diversity Network'>IPDN</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SITO' title='SITO Mobile, Ltd.'>SITO</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/NTWK' title='NetSol Technologies Inc.'>NTWK</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269092\" data-linked=\"Technology - Top Gainers / Losers as of 2:45 pm\" data-tweet=\"$PTE $AAOI $ACIA - Technology - Top Gainers / Losers as of 2:45 pm https://seekingalpha.com/news/3269092-technology-top-gainers-losers-of-2-45-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3269092-technology-top-gainers-losers-of-2-45-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:48 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269091\" data-ts=\"1495478874\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CYH\" target=\"_blank\">CYH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269091-community-health-nixes-talks-to-sell-indiana-hospitals-shares-ease-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Community Health nixes talks to sell Indiana hospitals; shares ease 2%</a></h4><ul><li>Community Heath Systems (<a href='https://seekingalpha.com/symbol/CYH' title='Community Health Systems, Inc.'>CYH</a> <font color='red'>-1.5%</font>) has terminated negotiations with a physician group that had offered $2.4B to buy the company's Fort Wayne, Indiana hospital network. The company says the doctors \"have failed to satisfy any reasonable criteria of a legitimate offer.\"</li><li>Source: The Fly</li></ul><div class=\"tiny-share-widget\" data-id=\"3269091\" data-linked=\"Community Health nixes talks to sell Indiana hospitals; shares ease 2%\" data-tweet=\"$CYH - Community Health nixes talks to sell Indiana hospitals; shares ease 2% https://seekingalpha.com/news/3269091-community-health-nixes-talks-to-sell-indiana-hospitals-shares-ease-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3269091-community-health-nixes-talks-to-sell-indiana-hospitals-shares-ease-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269090\" data-ts=\"1495478647\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CPB\" target=\"_blank\">CPB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269090-investors-nibble-on-food-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors nibble on food stocks</a></h4><ul> <li>Select food and beverage stocks are trading higher in a move that appears to be related to a favorable assessment on M&amp;A activity in the sector.</li><li>Campbell Soup (NYSE:<a href='https://seekingalpha.com/symbol/CPB' title='Campbell Soup Company'>CPB</a>) is <font color='green'>up 3.55%</font> to erase Friday's post-earnings slip.</li><li>Pinnacle Foods (NYSE:<a href='https://seekingalpha.com/symbol/PF' title='Pinnacle Foods'>PF</a>)&nbsp;<font color='green'>trades 2.87%</font>&nbsp;higher and carved out a new all-time high of $61.71 earlier this afternoon.</li> <li>J.J. Snack Foods (<a href='https://seekingalpha.com/symbol/JJSF' title='J & J Snack Foods Corp.'>JJSF</a> <font color='green'>+2.3%</font>), Post Holdings (<a href='https://seekingalpha.com/symbol/POST' title='Post Holdings, Inc.'>POST</a> <font color='green'>+1.3%</font>), Inventure Foods (<a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='green'>+2.8%</font>), Snyder's-Lance (<a href='https://seekingalpha.com/symbol/LNCE' title='Snyder&#39;s-Lance, Inc.'>LNCE</a> <font color='green'>+1.1%</font>), Freshpet (<a href='https://seekingalpha.com/symbol/FRPT' title='Freshpet'>FRPT</a> <font color='green'>+5.8%</font>), B&amp;G Foods (<a href='https://seekingalpha.com/symbol/BGS' title='B&G Foods, Inc.'>BGS</a> <font color='green'>+1.4%</font>), Unilever (<a href='https://seekingalpha.com/symbol/UN' title='Unilever NV'>UN</a> <font color='green'>+1.5%</font>), G. Willi-Food International (<a href='https://seekingalpha.com/symbol/WILC' title='G. Willi-Food International, Ltd.'>WILC</a> <font color='green'>+4.5%</font>), Cal-Maine Foods (<a href='https://seekingalpha.com/symbol/CALM' title='Cal-Maine Foods, Inc.'>CALM</a> <font color='green'>+2.8%</font>), Monster Beverage (<a href='https://seekingalpha.com/symbol/MNST' title='Monster Beverage Corp.'>MNST</a> <font color='green'>+1.5%</font>), National Beverage Corp (<a href='https://seekingalpha.com/symbol/FIZZ' title='National Beverage Corp.'>FIZZ</a> <font color='green'>+0.8%</font>), Lifeway Foods (<a href='https://seekingalpha.com/symbol/LWAY' title='Lifeway Foods, Inc.'>LWAY</a> <font color='green'>+1.5%</font>), Molson Coors (<a href='https://seekingalpha.com/symbol/TAP' title='Molson Coors Brewing Company'>TAP</a> <font color='green'>+1.3%</font>) and Pilgrim's Pride (<a href='https://seekingalpha.com/symbol/PPC' title='Pilgrim&#39;s Pride Corporation'>PPC</a> <font color='green'>+1.7%</font>) are also perky today.</li><li>Related ETF: <a href='https://seekingalpha.com/symbol/PBJ' title='Invesco Dynamic Food & Beverage Portfolio ETF'>PBJ</a>.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3269090\" data-linked=\"Investors nibble on food stocks\" data-tweet=\"$CPB $CPB $PF - Investors nibble on food stocks https://seekingalpha.com/news/3269090-investors-nibble-on-food-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3269090-investors-nibble-on-food-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:44 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269082\" data-ts=\"1495476104\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269082-energy-materials-top-gainers-losers-of-2-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top Gainers / Losers as of 2:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/FSI' title='Flexible Solutions International, Inc'>FSI</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/GST' title='Gastar Exploration Inc.'>GST</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/NOG' title='Northern Oil & Gas, Inc'>NOG</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/GSM' title='Ferroglobe PLC'>GSM</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/AXU' title='Alexco Resource Corporation'>AXU</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/SND' title='Smart Sand'>SND</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/CHKR' title='Chesapeake Granite Wash Trust'>CHKR</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/HCLP' title='Hi-Crush Partners LP'>HCLP</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/NRP' title='Natural Resource Partners LP'>NRP</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269082\" data-linked=\"Energy/Materials - Top Gainers / Losers as of 2:00 pm\" data-tweet=\"$FSI $GST $NOG - Energy/Materials - Top Gainers / Losers as of 2:00 pm https://seekingalpha.com/news/3269082-energy-materials-top-gainers-losers-of-2-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3269082-energy-materials-top-gainers-losers-of-2-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:01 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269080\" data-ts=\"1495475113\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269080-financials-top-5-gainers-losers-of-1-45-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:45 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ONDK' title='OnDeck Capital'>ONDK</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a> <font color='green'>+7%</font>.<a href='https://seekingalpha.com/symbol/XBKS' title='Xenith Bankshares, Inc.'>XBKS</a> <font color='green'>+6%</font>. IFMI <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/CFBK' title='Central Federal Corporation'>CFBK</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269080\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:45 PM\" data-tweet=\"$ONDK $BX $XBKS - Financials - Top 5 Gainers / Losers as of 1:45 PM https://seekingalpha.com/news/3269080-financials-top-5-gainers-losers-of-1-45-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3269080-financials-top-5-gainers-losers-of-1-45-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269079\" data-ts=\"1495474954\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ANFI\" target=\"_blank\">ANFI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269079-nutraceutical-takeover-shakes-up-wellness-sector\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nutraceutical takeover shakes up wellness sector</a></h4><ul> <li>Amira Nature Foods (<a href='https://seekingalpha.com/symbol/ANFI' title='Amira Nature Foods'>ANFI</a> <font color='green'>+3.1%</font>) and Natural Grocers by Vitamin Cottage (<a href='https://seekingalpha.com/symbol/NGVC' title='Natural Grocers'>NGVC</a> <font color='green'>+3.2%</font>) are both solidly higher after Nutraceutical is <a href=\"https://seekingalpha.com/news/3268970-hggc-takes-nutraceutical-private-446m\" target=\"_blank\">acquired</a>. Vitamin Shoppe (NYSE:<a href='https://seekingalpha.com/symbol/VSI' title='Vitamin Shoppe, Inc.'>VSI</a>) was up 3% earlier, but now trades flat on the day.</li> <li>Nutraceutical trades above the $41.80 per share offered by HGGC, indicating that the M&amp;A vibe in the natural/nutritional sector is still percolating.</li> <li>Related: <a href=\"https://seekingalpha.com/news/3268962-gnc-holdings-pops-nutraceutical-takeover\" target=\"_blank\">GNC Holdings pops after Nutraceutical takeover</a> (May 22)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3269079\" data-linked=\"Nutraceutical takeover shakes up wellness sector\" data-tweet=\"$ANFI $ANFI $NGVC - Nutraceutical takeover shakes up wellness sector https://seekingalpha.com/news/3269079-nutraceutical-takeover-shakes-up-wellness-sector?source=tweet\" data-url=\"https://seekingalpha.com/news/3269079-nutraceutical-takeover-shakes-up-wellness-sector\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269070\" data-ts=\"1495471547\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269070-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NUTR' title='Nutraceutical International Corporation'>NUTR</a> <font color='green'>+50%</font>. <a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+42%</font>. <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/MNKD' title='MannKind Corporation'>MNKD</a> <font color='green'>+19%</font>. COOL <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/FSI' title='Flexible Solutions International, Inc'>FSI</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/GSM' title='Ferroglobe PLC'>GSM</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/GST' title='Gastar Exploration Inc.'>GST</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a> <font color='green'>+11%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CCCR-OLD' title='China Commercial Credit'>CCCR-OLD</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/SAUC' title='Diversified Restaurant Holdings'>SAUC</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/TWMC' title='Trans World Entertainment Corp.'>TWMC</a> <font color='red'>-14%</font>. HOTR <font color='red'>-13%</font>. <a href='https://seekingalpha.com/symbol/FRTA' title='Forterra'>FRTA</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-11%</font>. <a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='red'>-10%</font>. <a href='https://seekingalpha.com/symbol/GOL' title='GOL Linhas Areas Inteligentes S.A.'>GOL</a> <font color='red'>-9%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269070\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$NUTR $PBYI $SORL - Midday Gainers / Losers https://seekingalpha.com/news/3269070-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3269070-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:45 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269068\" data-ts=\"1495470861\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HUN\" target=\"_blank\">HUN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269068-investors-cool-to-huntsman-in-clariant-merger-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors cool to Huntsman in Clariant merger deal</a></h4><ul>     <li>Huntsman (<a href='https://seekingalpha.com/symbol/HUN' title='Huntsman Corporation'>HUN</a> <font color='red'>-1.8%</font>) drifts steadily lower following its <a href=\"https://seekingalpha.com/news/3268929-huntsman-clariant-announce-merger-deal\" target=\"_blank\">merger of equals</a> with Switzerland-based Clariant (<a href='https://seekingalpha.com/symbol/CLZNF' title='Clariant AG'>OTCPK:CLZNF</a>, <a href='https://seekingalpha.com/symbol/CLZNY' title='Clariant AG ADR'>OTCPK:CLZNY</a>), as investors may have been <a href=\"https://twitter.com/thenotablecalls/status/866658551829286912\" target=\"_blank\">expecting an outright takeover</a> of the company.</li>     <li>Reuters' Olaf Storbeck notes <a href=\"https://www.breakingviews.com/considered-view/clariant-huntsman-tests-formula-for-big-ma/\" target=\"_blank\">the deal's timing</a>, as HUN&rsquo;s shares have been on an impressive run for months, sparked by a plan to list its Venator pigments and additives business separately, as well as by the wider U.S. stock market rally.</li>     <li><em>WSJ</em>&nbsp;Heard On The Street's Paul&nbsp;Davies favors the deal but <a href=\"https://www.wsj.com/articles/huntsman-clariant-a-chemical-experiment-worth-pursuing-1495461442\" target=\"_blank\">questions the anticipated $400M cost savings</a>; $250M is supposed to come from combined corporate functions and infrastructure but says the savings could be hard to find given the proposed structure - HuntsmanClariant will have two headquarters, one in Switzerland and one in Texas - and the companies make different chemicals in different factories and do not expect to cut staff or production facilities.</li>     <li>Also, HUN&rsquo;s debt will give the combined group net debt worth more than 2.6x its 2016 EBITDA, although the planned eventual $2B sale of the pigments and additives business would cut the ratio to less than 1.5x, better than either company today.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269068\" data-linked=\"Investors cool to Huntsman in Clariant merger deal\" data-tweet=\"$HUN $HUN $CLZNF - Investors cool to Huntsman in Clariant merger deal https://seekingalpha.com/news/3269068-investors-cool-to-huntsman-in-clariant-merger-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3269068-investors-cool-to-huntsman-in-clariant-merger-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:34 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>23&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269066\" data-ts=\"1495469823\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NURO\" target=\"_blank\">NURO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269066-neurometrix-awarded-new-u-s-patent-covering-pain-relief-device-quell-shares-up-6\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NeuroMetrix awarded new U.S. patent covering pain relief device Quell; shares up 6%</a></h4><ul><li>Thinly traded nano cap NeuroMetrix (<a href='https://seekingalpha.com/symbol/NURO' title='NeuroMetrix, Inc.'>NURO</a> <font color='green'>+6%</font>) turns from red to green for the session after it <a href=\"https://seekingalpha.com/pr/16840086-neurometrix-announces-issuance-new-u-s-patent-quell-wearable-pain-relief-technology\" target=\"_blank\">announced </a>that the USPTO has issued Patent No. 9,656,070 protecting its Quell device. The patent covers the novel application of real-time accelerometer measurements to control transcutaneous electrical nerve stimulation.</li><li><a href=\"https://www.quellrelief.com/\" target=\"_blank\">Quell&nbsp;</a>is a neurostimulation device that is worn around the upper calf to provide pain relief due to diabetes, fibromyalgia, arthritis and in the lower back and leg.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269066\" data-linked=\"NeuroMetrix awarded new U.S. patent covering pain relief device Quell; shares up 6%\" data-tweet=\"$NURO - NeuroMetrix awarded new U.S. patent covering pain relief device Quell; shares up 6% https://seekingalpha.com/news/3269066-neurometrix-awarded-new-u-s-patent-covering-pain-relief-device-quell-shares-up-6?source=tweet\" data-url=\"https://seekingalpha.com/news/3269066-neurometrix-awarded-new-u-s-patent-covering-pain-relief-device-quell-shares-up-6\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269064\" data-ts=\"1495468853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269064-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/NUTR' title='Nutraceutical International Corporation'>NUTR</a> <font color='green'>+50%</font>. <a href='https://seekingalpha.com/symbol/SORL' title='SORL Auto Parts, Inc.'>SORL</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/FRPT' title='Freshpet'>FRPT</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/LBY' title='Libbey Inc.'>LBY</a> <font color='green'>+7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269064\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$NUTR $SORL $NBEV - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3269064-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3269064-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269060\" data-ts=\"1495468376\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EDAP\" target=\"_blank\">EDAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269060-u-s-reimbursement-outlook-for-edaps-hifu-in-prostate-cancer-improves-establishment-of-new\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. reimbursement outlook for EDAP&#39;s HIFU in prostate cancer improves with establishment of new billing code; shares up 11%</a></h4><ul><li>Thinly traded nano cap EDAP TMS SA (<a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a> <font color='green'>+10.7%</font>) heads north on a 12x surge in volume, albeit on only 257K shares, in response to its <a href=\"https://seekingalpha.com/pr/16839722-edap-announces-cms-approval-new-reimbursement-code-hifu-ablation-prostate\" target=\"_blank\">announcement </a>that the U.S. Centers for Medicare and Medicaid Services has established a separate billing code for HIFU ablation of prostate tissue that will take effect on July 1.</li><li>The new reimbursement code, which has assigned a \"competitive\" coverage level, should make it easier for doctors receive payment from procedures performed with the company's Ablatherm, including primary whole gland prostate ablation, partial prostate ablation or whole/partial salvage ablation.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269060\" data-linked=\"U.S. reimbursement outlook for EDAP&#39;s HIFU in prostate cancer improves with establishment of new billing code; shares up 11%\" data-tweet=\"$EDAP - U.S. reimbursement outlook for EDAP&#39;s HIFU in prostate cancer improves with establishment of new billing code; shares up 11% https://seekingalpha.com/news/3269060-u-s-reimbursement-outlook-for-edaps-hifu-in-prostate-cancer-improves-establishment-of-new?source=tweet\" data-url=\"https://seekingalpha.com/news/3269060-u-s-reimbursement-outlook-for-edaps-hifu-in-prostate-cancer-improves-establishment-of-new\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269030\" data-ts=\"1495465308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269030-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+61%</font>. <a href='https://seekingalpha.com/symbol/RDUS' title='Radius Health, Inc.'>RDUS</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/EDAP' title='EDAP TMS S.A.'>EDAP</a> <font color='green'>+11%</font>. <a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/IMDZ' title='Immune Design'>IMDZ</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/GALT' title='Galectin Therapeutics, Inc.'>GALT</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/QHC' title='Quorum Health Corporation'>QHC</a> <font color='red'>-12%</font>. <a href='https://seekingalpha.com/symbol/NBY' title='NovaBay Pharmaceuticals, Inc.'>NBY</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='red'>-7%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269030\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$PBYI $RDUS $EDAP - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3269030-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3269030-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:01 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269050\" data-ts=\"1495465222\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INNV\" target=\"_blank\">INNV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269050-innovus-pharma-inks-zestra-distribution-deal-in-asia-pacific-shares-ahead-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Innovus Pharma inks Zestra distribution deal in Asia-Pacific; shares ahead 5%</a></h4><ul><li>Innovus Pharma (<a href='https://seekingalpha.com/symbol/INNV' title='Innovus Pharmaceuticals, Inc.'>OTCQB:INNV</a> <font color='green'>+5.1%</font>) enters into an exclusive license and distribution <a href=\"https://seekingalpha.com/pr/16839343-innovus-pharma-signs-exclusive-license-distribution-agreement-luminarie-australia-new-zealand\" target=\"_blank\">agreement </a>with Australia-based Luminarie Pty Ltd. for the commercialization of Zestra and Zestra Glide in Australia, New Zealand and the Philippines.</li><li>Financial terms are not disclosed.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269050\" data-linked=\"Innovus Pharma inks Zestra distribution deal in Asia-Pacific; shares ahead 5%\" data-tweet=\"$INNV - Innovus Pharma inks Zestra distribution deal in Asia-Pacific; shares ahead 5% https://seekingalpha.com/news/3269050-innovus-pharma-inks-zestra-distribution-deal-in-asia-pacific-shares-ahead-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3269050-innovus-pharma-inks-zestra-distribution-deal-in-asia-pacific-shares-ahead-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269049\" data-ts=\"1495464765\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MBVX\" target=\"_blank\">MBVX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269049-mabvax-closes-4_1m-equity-offering-shares-down-4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">MabVax closes $4.1M equity offering; shares down 4%</a></h4><ul><li>MabVax (<a href='https://seekingalpha.com/symbol/MBVX' title='MABVAX THERAPEUTICS HLDGS'>OTCPK:MBVX</a> <font color='red'>-3.9%</font>) <a href=\"https://seekingalpha.com/pr/16839378-mabvax-therapeutics-announces-closing-4_1-million-public-offering\" target=\"_blank\">closes </a>its public offering of common and preferred stock that yielded gross proceeds of $4.1M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3267591-mabvax-announces-4_1m-offering-fund-trials\" target=\"_blank\">MabVax announces $4.1M offering to fund trials</a> (May 15)</li></ul><div class=\"tiny-share-widget\" data-id=\"3269049\" data-linked=\"MabVax closes $4.1M equity offering; shares down 4%\" data-tweet=\"$MBVX $MBVXQ - MabVax closes $4.1M equity offering; shares down 4% https://seekingalpha.com/news/3269049-mabvax-closes-4_1m-equity-offering-shares-down-4?source=tweet\" data-url=\"https://seekingalpha.com/news/3269049-mabvax-closes-4_1m-equity-offering-shares-down-4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269047\" data-ts=\"1495464503\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XENT\" target=\"_blank\">XENT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269047-fda-action-date-january-7-for-intersect-ents-sinuva-implant-shares-up-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA action date January 7 for Intersect ENT&#39;s Sinuva implant; shares up 1%</a></h4><ul><li>Intersect ENT (<a href='https://seekingalpha.com/symbol/XENT' title='Intersect ENT'>XENT</a> <font color='green'>+0.9%</font>) <a href=\"https://seekingalpha.com/pr/16839364-intersect-ent-announces-pdufa-date-office-based-sinuva-steroid-releasing-sinus-implant\" target=\"_blank\">announces </a>that the FDA's action date &#40;PDUFA&#41; for the review of its New Drug Application &#40;NDA&#41; seeking approval of the SINUVA Steroid-Releasing Sinus Implant is January 7, 2018. Since this is a Sunday, investors should expect the decision on or about Friday, January 5.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269047\" data-linked=\"FDA action date January 7 for Intersect ENT&#39;s Sinuva implant; shares up 1%\" data-tweet=\"$XENT - FDA action date January 7 for Intersect ENT&#39;s Sinuva implant; shares up 1% https://seekingalpha.com/news/3269047-fda-action-date-january-7-for-intersect-ents-sinuva-implant-shares-up-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3269047-fda-action-date-january-7-for-intersect-ents-sinuva-implant-shares-up-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:48 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269043\" data-ts=\"1495463853\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BSTG\" target=\"_blank\">BSTG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269043-biostage-still-short-on-nasdaq-listing-requirements-faces-delisting-shares-down-21\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biostage still short on Nasdaq listing requirements, faces delisting; shares down 21%</a></h4><ul><li>Biostage (<a href='https://seekingalpha.com/symbol/BSTG' title='Biostage, Inc.'>OTC:BSTG</a> <font color='red'>-21%</font>) slumps on increased volume after its <a href=\"https://seekingalpha.com/filing/3561127\" target=\"_blank\">announcement</a> that it may be delisted from Nasdaq due to it failure to rectify deficiencies related to minimum bid price ($1/share) and minimum stockholders' equity ($2.5M).</li><li>The company says it will request a hearing before the Hearings Panel during which it will present its plan to address the issues and request an extension of the deadline (no later than November 14).</li></ul><div class=\"tiny-share-widget\" data-id=\"3269043\" data-linked=\"Biostage still short on Nasdaq listing requirements, faces delisting; shares down 21%\" data-tweet=\"$BSTG - Biostage still short on Nasdaq listing requirements, faces delisting; shares down 21% https://seekingalpha.com/news/3269043-biostage-still-short-on-nasdaq-listing-requirements-faces-delisting-shares-down-21?source=tweet\" data-url=\"https://seekingalpha.com/news/3269043-biostage-still-short-on-nasdaq-listing-requirements-faces-delisting-shares-down-21\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269037\" data-ts=\"1495463009\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269037-briefing-docs-out-for-ad-comm-review-of-pumas-neratinib-shares-up-52\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Briefing docs out for Ad Comm review of Puma&#39;s neratinib; shares up 52%</a></h4><ul><li>Puma Biotechnology (<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a> <font color='green'>+51.5%</font>)&nbsp;rockets on average volume after the release of the briefing materials for Wednesday's FDA advisory committee review of its New Drug Application &#40;NDA&#41; seeking approval of neratinib, branded as NERLYNX, for extended adjuvant treatment of patients with HER2+ breast cancer who have been previously treated with Roche's Herceptin (trastuzumab).</li><li>Longs are apparently giddy over the positive implications of the third bullet under Topics of Discussion: \"The totality of evidence of neratinib's efficacy data in the context of other approvals in the adjuvant setting.\" The data show a similar rate of benefit, measured by disease-free survival, when compared to approvals of adjuvant hormonal therapies, but \"with a different toxicity profile.\"</li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM559721.pdf\" target=\"_blank\">FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM559724.pdf\" target=\"_blank\">Errata to FDA briefing doc</a></li><li><a href=\"https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM559728.pdf\" target=\"_blank\">Puma briefing doc&nbsp;</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3269037\" data-linked=\"Briefing docs out for Ad Comm review of Puma&#39;s neratinib; shares up 52%\" data-tweet=\"$PBYI - Briefing docs out for Ad Comm review of Puma&#39;s neratinib; shares up 52% https://seekingalpha.com/news/3269037-briefing-docs-out-for-ad-comm-review-of-pumas-neratinib-shares-up-52?source=tweet\" data-url=\"https://seekingalpha.com/news/3269037-briefing-docs-out-for-ad-comm-review-of-pumas-neratinib-shares-up-52\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269038\" data-ts=\"1495462277\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EKSO\" target=\"_blank\">EKSO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269038-ekso-bionics-on-move\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ekso Bionics on the move</a></h4><ul><li><a href='https://seekingalpha.com/symbol/EKSO' title='Ekso Bionics Holdings, Inc.'>EKSO</a> starts the week on the back foot, <font color='red'>plunging over 16%</font> in early trade.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269038\" data-linked=\"Ekso Bionics on the move\" data-tweet=\"$EKSO - Ekso Bionics on the move https://seekingalpha.com/news/3269038-ekso-bionics-on-move?source=tweet\" data-url=\"https://seekingalpha.com/news/3269038-ekso-bionics-on-move\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>19&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269034\" data-ts=\"1495461742\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ALR\" target=\"_blank\">ALR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269034-alere-q4-top-line-off-3-loss-share-of-1_41-shares-up-2-on-resolution-accounting-errors-in\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Alere Q4 top line off 3%; loss/share of $1.41; shares up 2% on resolution accounting errors in South Korea</a></h4><ul><li>On a<a href=\"https://seekingalpha.com/pr/16839838-alere-announces-update-form-10-k-provides-preliminary-unaudited-financial-results\" target=\"_blank\"> preliminary basis</a>, Alere (<a href='https://seekingalpha.com/symbol/ALR' title='Alere Inc.'>ALR</a> <font color='green'>+2.3%</font>) booked $597M in revenues for Q4 2016, down 3.2%. GAAP loss/share was ($1.41).</li><li>For the year, revenues were $2.38B (-2.9%) with a loss/share of ($1.86).</li><li>The company says it should complete its previously announced review of its financials and file its 2016 10-K by June 15. It had delayed filing while it investigated financial misstatements by its subsidiary in South Korea. The adjustments to correct errors in revenue recognition are minor.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269034\" data-linked=\"Alere Q4 top line off 3%; loss/share of $1.41; shares up 2% on resolution accounting errors in South Korea\" data-tweet=\"$ALR - Alere Q4 top line off 3%; loss/share of $1.41; shares up 2% on resolution accounting errors in South Korea https://seekingalpha.com/news/3269034-alere-q4-top-line-off-3-loss-share-of-1_41-shares-up-2-on-resolution-accounting-errors-in?source=tweet\" data-url=\"https://seekingalpha.com/news/3269034-alere-q4-top-line-off-3-loss-share-of-1_41-shares-up-2-on-resolution-accounting-errors-in\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269031\" data-ts=\"1495461595\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UBSH\" target=\"_blank\">UBSH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269031-union-bankshares-to-buy-xenith-bankshares-in-all-stock-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Union Bankshares to buy Xenith Bankshares in all-stock deal</a></h4><ul>     <li>Union Bankshares (<a href='https://seekingalpha.com/symbol/UBSH' title='Union Bankshares Corporation'>UBSH</a> <font color='red'>-2.9%</font>) <a href=\"https://seekingalpha.com/pr/16839538-union-bankshares-corporation-announces-agreement-acquire-xenith-bankshares-inc\" target=\"_blank\">agrees to acquire</a> Xenith Bankshares (<a href='https://seekingalpha.com/symbol/XBKS' title='Xenith Bankshares, Inc.'>XBKS</a> <font color='green'>+3.6%</font>) in an all-stock deal <a href=\"https://www.reuters.com/article/us-xenith-bnkshares-m-a-union-bankshares-idUSKBN18I1FX\" target=\"_blank\">valued at nearly $695M</a>, as the bank seeks to expand into North Carolina and Maryland.</li>     <li>UBSH's offer of 0.9354 shares for each XBKS share translates to $29.67/share and is a 10.4% premium to XBKS's Friday close.</li>     <li>UBSH says the combined company would have total assets of $11.9B, total deposits of $9.2B and gross loans of $8.9B.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269031\" data-linked=\"Union Bankshares to buy Xenith Bankshares in all-stock deal\" data-tweet=\"$UBSH $AUB $XBKS - Union Bankshares to buy Xenith Bankshares in all-stock deal https://seekingalpha.com/news/3269031-union-bankshares-to-buy-xenith-bankshares-in-all-stock-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3269031-union-bankshares-to-buy-xenith-bankshares-in-all-stock-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:59 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269028\" data-ts=\"1495461374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NKE\" target=\"_blank\">NKE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269028-bank-of-america-merrill-lynch-still-negative-on-nike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank of America Merrill Lynch still negative on Nike</a></h4><ul> <li>Bank of America Merrill Lynch issues a weak outlook on Nike (<a href='https://seekingalpha.com/symbol/NKE' title='Nike Inc.'>NKE</a> <font color='red'>-0.2%</font>) ahead of the back-to-school season.</li> <li>The myriad of concerns that are part of BAML's negative view (Underperform, $42 price target) on Nike include the high inventory levels, market share loss to Adidas and weak sell-through rates in some key premium categories.</li> <li>The investment firm's position on Nike makes it an outlier - with 22 Buys, 14 Holds and one lonely Sell rating on the books from Wall Street firms.</li> <li>Source: Bloomberg</li> <li>Shares of Nike are up 1.81% YTD vs. +7.03% for the S&amp;P 500 Index.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269028\" data-linked=\"Bank of America Merrill Lynch still negative on Nike\" data-tweet=\"$NKE - Bank of America Merrill Lynch still negative on Nike https://seekingalpha.com/news/3269028-bank-of-america-merrill-lynch-still-negative-on-nike?source=tweet\" data-url=\"https://seekingalpha.com/news/3269028-bank-of-america-merrill-lynch-still-negative-on-nike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269026\" data-ts=\"1495460494\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIOC\" target=\"_blank\">BIOC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269026-biocept-nabs-broad-patent-covering-liquid-biopsy-shares-up-15\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Biocept nabs broad patent covering liquid biopsy; shares up 15%</a></h4><ul><li>Biocept (<a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='green'>+14.7%</font>) is up out of the blocks this morning on the <a href=\"https://seekingalpha.com/pr/16839548-biocept-awarded-u-s-patent-broad-claims-antibody-capture-targets-interest-solid-surface\" target=\"_blank\">news </a>that &nbsp;the USPTO has issued it U.S. Patent No. 9,671,407 covering the broad use of antibodies for the capture of any target of interest on any solid surface from any sample type, including a range of targets shed by solid tumors into the bloodstream.</li><li>Chief Scientific Officer Lyle Arnold, Ph.D. says, \"The granting of this patent significantly expands Biocept's intellectual property rights regarding the use of 'cocktails' of antibodies for the capture of any target of interest. The expansion of this platform complements nicely with Biocept's circulating tumor DNA (ctDNA) platform and allows us to provide an expanded set of biomarker content to aid physicians in making optimal treatment decisions for their cancer patients.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3269026\" data-linked=\"Biocept nabs broad patent covering liquid biopsy; shares up 15%\" data-tweet=\"$BIOC - Biocept nabs broad patent covering liquid biopsy; shares up 15% https://seekingalpha.com/news/3269026-biocept-nabs-broad-patent-covering-liquid-biopsy-shares-up-15?source=tweet\" data-url=\"https://seekingalpha.com/news/3269026-biocept-nabs-broad-patent-covering-liquid-biopsy-shares-up-15\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:41 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269023\" data-ts=\"1495459641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYEG\" target=\"_blank\">EYEG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269023-eyegate-receives-first-milestone-payment-from-valeant-related-to-development-of-egpminus-437\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EyeGate receives first milestone payment from Valeant related to development of EGP-437; shares ahead 15% premarket</a></h4><ul><li>EyeGate Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a>) is up&nbsp;<font color='green'>15%</font>&nbsp;premarket on average volume in response to its <a href=\"https://seekingalpha.com/pr/16839428-eyegate-receives-milestone-payment-valeant-pharmaceuticals-egpminus-437-post-operative-ocular\" target=\"_blank\">announcement </a>that it has received its first milestone payment from licensee Valeant Pharmaceuticals related to the development of EGP-437.</li><li>Valeant has exclusive global rights to the EyeGate II Delivery System and EGP-437 for the treatment of post-operative inflammation and pain in ocular surgery patients. EyeGate is eligible to receive up to $99M in milestones plus royalties under the arrangement.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269023\" data-linked=\"EyeGate receives first milestone payment from Valeant related to development of EGP-437; shares ahead 15% premarket\" data-tweet=\"$EYEG - EyeGate receives first milestone payment from Valeant related to development of EGP-437; shares ahead 15% premarket https://seekingalpha.com/news/3269023-eyegate-receives-first-milestone-payment-from-valeant-related-to-development-of-egpminus-437?source=tweet\" data-url=\"https://seekingalpha.com/news/3269023-eyegate-receives-first-milestone-payment-from-valeant-related-to-development-of-egpminus-437\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269020\" data-ts=\"1495459525\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIO\" target=\"_blank\">RIO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269020-rio-tinto-to-reduce-debt-much-2_5b\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rio Tinto to reduce debt by as much as $2.5B</a></h4><ul>     <li>Rio Tinto (NYSE:<a href='https://seekingalpha.com/symbol/RIO' title='Rio Tinto plc'>RIO</a>)&nbsp;<font color='green'>+2.1%</font> premarket after announcing a <a href=\"https://seekingalpha.com/pr/16839657-rio-tinto-launches-new-debt-reduction-programme-2_5-billion\" target=\"_blank\">new bond buyback of up to $2.5B</a> in an effort to cut debt.</li>     <li>Rio says it issued a redemption notice for $1.72B of its 2019 and 2020 dollar-denominated notes and a cash tender offer to buy $781M of its five 2021, 2022 and 2025 notes.</li>     <li>Rio says the new debt reduction program follows the completion of a series of $7.5B U.S. dollar-denominated note redemptions and repurchases in 2016.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269020\" data-linked=\"Rio Tinto to reduce debt by as much as $2.5B\" data-tweet=\"$RIO - Rio Tinto to reduce debt by as much as $2.5B https://seekingalpha.com/news/3269020-rio-tinto-to-reduce-debt-much-2_5b?source=tweet\" data-url=\"https://seekingalpha.com/news/3269020-rio-tinto-to-reduce-debt-much-2_5b\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269019\" data-ts=\"1495459451\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269019-premarket-gainers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers as of 9:05 am</a></h4><ul><li><a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='green'>+21%</font>&nbsp;on being awarded broad claims for antibody capture of targets of interest on any solid surface.</li><li><a href='https://seekingalpha.com/symbol/CMCM' title='Cheetah Mobile Inc.'>CMCM</a> <font color='green'>+16%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3268947-cheetah-mobile-beats-0_09-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/EYEG' title='EyeGate Pharmaceuticals'>EYEG</a> <font color='green'>+15%</font>&nbsp;received its first development milestone payment from Valeant Pharmaceuticals (<a href=\"https://seekingalpha.com/symbol/vrx\" target=\"_blank\">VRX</a>).&nbsp;</li><li><a href='https://seekingalpha.com/symbol/RDUS' title='Radius Health, Inc.'>RDUS</a> <font color='green'>+14%</font>&nbsp;on Amgen's announcement of late-stage results for osteoporosis candidate EVENITY.</li><li><a href='https://seekingalpha.com/symbol/NTNX' title='Nutanix'>NTNX</a> <font color='green'>+9%</font>&nbsp;on announcing the private cloud deployment of SAIC Volkswagen.</li><li><a href='https://seekingalpha.com/symbol/FBRC' title='FBR & Co.'>FBRC</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a> <font color='green'>+6%</font>&nbsp;on signing a memorandum of understanding with Saudi Arabia's PIF sovereign wealth fund.</li><li><a href='https://seekingalpha.com/symbol/HUN' title='Huntsman Corporation'>HUN</a> <font color='green'>+6%</font>&nbsp;on merger with Clariant (<a href='https://seekingalpha.com/symbol/CLZNF' title='Clariant AG'>OTCPK:CLZNF</a>).</li><li><a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a> <font color='green'>+6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269019\" data-linked=\"Premarket Gainers as of 9:05 am\" data-tweet=\"$BIOC $CMCM $EYEG - Premarket Gainers as of 9:05 am https://seekingalpha.com/news/3269019-premarket-gainers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3269019-premarket-gainers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269017\" data-ts=\"1495459311\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PBYI\" target=\"_blank\">PBYI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269017-ad-comm-review-wednesday-on-pumas-neratinib-in-her2-positive-breast-cancer-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ad Comm review Wednesday on Puma&#39;s neratinib in HER2-positive breast cancer; shares up 3% premarket</a></h4><ul><li>The FDA's Oncologic Drug Advisory Committee will <a href=\"https://www.fda.gov/AdvisoryCommittees/Calendar/ucm553431.htm\" target=\"_blank\">meet </a>on Wednesday, May 24, to discuss Puma Biotechnology's (NYSE:<a href='https://seekingalpha.com/symbol/PBYI' title='Puma Biotechnology, Inc.'>PBYI</a>) New Drug Application &#40;NDA&#41; seeking approval of neratinib for the treatment of HER2+ breast cancer. Shares are up&nbsp;<font color='green'>3%&nbsp;</font>premarket ahead of the release of briefing docs.</li></ul><div class=\"tiny-share-widget\" data-id=\"3269017\" data-linked=\"Ad Comm review Wednesday on Puma&#39;s neratinib in HER2-positive breast cancer; shares up 3% premarket\" data-tweet=\"$PBYI - Ad Comm review Wednesday on Puma&#39;s neratinib in HER2-positive breast cancer; shares up 3% premarket https://seekingalpha.com/news/3269017-ad-comm-review-wednesday-on-pumas-neratinib-in-her2-positive-breast-cancer-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3269017-ad-comm-review-wednesday-on-pumas-neratinib-in-her2-positive-breast-cancer-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:21 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269014\" data-ts=\"1495458665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269014-premarket-losers-of-9-05\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Losers as of 9:05 am</a></h4><ul>     <li><a href='https://seekingalpha.com/symbol/IDXG' title='Interpace Diagnostics Group, Inc.'>IDXG</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a>&nbsp;<font color='red'>-9%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3269008-la-jollas-ljpcminus-501-achieves-primary-endpoint-late-stage-study-patients-life-threatening\" target=\"_blank\">announcing</a> results from&nbsp;Phase 3 ATHOS-3 study assessing LJPC-501.</li><li><a href='https://seekingalpha.com/symbol/SNCR' title='Synchronoss Technologies, Inc.'>SNCR</a> <font color='red'>-6%</font>.</li><li><a href='https://seekingalpha.com/symbol/GLYC' title='GlycoMimetics'>GLYC</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3269014\" data-linked=\"Premarket Losers as of 9:05 am\" data-tweet=\"$IDXG $LJPC $SNCR - Premarket Losers as of 9:05 am https://seekingalpha.com/news/3269014-premarket-losers-of-9-05?source=tweet\" data-url=\"https://seekingalpha.com/news/3269014-premarket-losers-of-9-05\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269008\" data-ts=\"1495457886\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LJPC\" target=\"_blank\">LJPC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269008-la-jollas-ljpcminus-501-achieves-primary-endpoint-in-late-stage-study-in-patients-life\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">La Jolla&#39;s LJPC-501 achieves primary endpoint in late-stage study in patients with life-threatening drop in blood pressure; shares down 10% premarket on disappointing effect on mortality</a></h4><ul><li>La Jolla Pharmaceutical (NASDAQ:<a href='https://seekingalpha.com/symbol/LJPC' title='La Jolla Pharmaceutical Co.'>LJPC</a>) slumps&nbsp;<font color='red'>10%</font>&nbsp;premarket on light volume after the company <a href=\"https://seekingalpha.com/pr/16839204-results-athosminus-3-phase-3-study-ljpcminus-501-published-new-england-journal-medicine\" target=\"_blank\">announced </a>that results from its Phase 3 ATHOS-3 study assessing LJPC-501 (angiotensin II) in patients with catecholamine-resistant hypotension have been published online by <em>The New England Journal of Medicin</em>e.</li><li><a href=\"https://clinicaltrials.gov/ct2/show/NCT02338843?term=ljpc-501&amp;phase=2&amp;rank=1\" target=\"_blank\">ATHOS-3</a> met its primary endpoint of a statistically valid increase in the proportion of patients achieving a mean arterial pressure &#40;MAP&#41; of at least 75 mmHg or a 10 mmHg increase from baseline MAP three hours following the initiation of treatment without an increase in standard-of-care vasopressors (69.9% vs. 23.4%; p&lt;0.001).</li><li>The study showed a \"trend\" toward longer survival in the angiotensin II-treated group but it fell short of statistical significance (p=0.12).</li><li>The incidence of adverse events favored the treatment group (87.1% vs. 91.8%) over placebo as did the discontinuation rate (14.1% vs. 21.5%).</li></ul><div class=\"tiny-share-widget\" data-id=\"3269008\" data-linked=\"La Jolla&#39;s LJPC-501 achieves primary endpoint in late-stage study in patients with life-threatening drop in blood pressure; shares down 10% premarket on disappointing effect on mortality\" data-tweet=\"$LJPC - La Jolla&#39;s LJPC-501 achieves primary endpoint in late-stage study in patients with life-threatening drop in blood pressure; shares down 10% premarket on disappointing effect on mortality https://seekingalpha.com/news/3269008-la-jollas-ljpcminus-501-achieves-primary-endpoint-in-late-stage-study-in-patients-life?source=tweet\" data-url=\"https://seekingalpha.com/news/3269008-la-jollas-ljpcminus-501-achieves-primary-endpoint-in-late-stage-study-in-patients-life\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269007\" data-ts=\"1495457844\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AEG\" target=\"_blank\">AEG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269007-aegon-to-sell-of-u-s-run-off-businesses\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Aegon to sell most of U.S. run-off businesses</a></h4><ul>     <li>Aegon (NYSE:<a href='https://seekingalpha.com/symbol/AEG' title='AEGON NV'>AEG</a>) <font color='green'>+2.4%</font> premarket after <a href=\"https://www.aegon.com/en/Home/Investors/News-releases/2017/aegon-to-divest-majority-of-us-run-off-businesses/\" target=\"_blank\">agreeing to sell</a> its two largest U.S. run-off businesses, the payout annuity business and the bank owned/corporate owned life insurance business, to Wilton Re.</li>     <li>AEG says its Transamerica life subsidiaries will  reinsure $14B of liabilities to affiliates of Wilton Re U.S. Holding, and the company expects the deal to result in a  ~$700M capital release in 2017.</li><li>AEG expects its Group Solvency II ratio to improve by six percentage points in H2 2017 as a result of the deal.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269007\" data-linked=\"Aegon to sell most of U.S. run-off businesses\" data-tweet=\"$AEG - Aegon to sell most of U.S. run-off businesses https://seekingalpha.com/news/3269007-aegon-to-sell-of-u-s-run-off-businesses?source=tweet\" data-url=\"https://seekingalpha.com/news/3269007-aegon-to-sell-of-u-s-run-off-businesses\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269002\" data-ts=\"1495456761\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/F\" target=\"_blank\">F</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269002-ford-confirms-new-ceo-and-strategy-reset\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ford confirms new CEO and strategy reset</a></h4><ul> <li>Ford (NYSE:<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a>) <a href=\"https://seekingalpha.com/pr/16839575-ford-appoints-jim-hackett-ceo-strengthen-operations-transform-future-farley-hinrichs-klevorn\" target=\"_blank\">confirms</a> earlier reports that Jim Hackett will take over for the retiring Mark Fields. \"Jim Hackett is the right CEO to lead Ford during this transformative period for the auto industry and the broader mobility space,\" says Executive Chairman Bill Ford.</li> <li>The company says Hackett is tasked with the top priorities of sharpening operational execution, modernizing Ford&rsquo;s present business and transforming the company to meet tomorrow&rsquo;s challenges.</li> <li>A number of other key roles under Hackett were assigned by Ford, including the naming of Marcy Klevorn as the new VP of mobility.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3268925-fords-ceo-fields-shown-door\" target=\"_blank\">Ford's CEO Fields to be shown the door</a> (May 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3268961-ford-higher-ceo-shakeup\" target=\"_blank\">Ford higher after CEO shakeup</a> (May 22)</li> <li>Ford <font color='green'>+2.12%</font> premarket to $11.10.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3269002\" data-linked=\"Ford confirms new CEO and strategy reset\" data-tweet=\"$F - Ford confirms new CEO and strategy reset https://seekingalpha.com/news/3269002-ford-confirms-new-ceo-and-strategy-reset?source=tweet\" data-url=\"https://seekingalpha.com/news/3269002-ford-confirms-new-ceo-and-strategy-reset\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:39 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>52&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3269000\" data-ts=\"1495456665\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCIX\" target=\"_blank\">DCIX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3269000-diana-containerships-beats-0_05-misses-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Diana Containerships beats by $0.05, misses on revenue</a></h4><ul><li>Diana Containerships (NASDAQ:<a href='https://seekingalpha.com/symbol/DCIX' title='Diana Containerships Inc.'>DCIX</a>): Q1 EPS of -$0.80 <font color='green'>beats by $0.05</font>.</li><li>Revenue of $3.78M (-67.9% Y/Y) <font color='red'>misses by $2.82M</font>.</li><li>Shares <font color='green'>+3.19%</font> PM.</li><li><a href='https://seekingalpha.com/pr/16839634-diana-containerships-inc-reports-financial-results-first-quarter-ended-march-31-2017'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3269000\" data-linked=\"Diana Containerships beats by $0.05, misses on revenue\" data-tweet=\"$DCIX - Diana Containerships beats by $0.05, misses on revenue https://seekingalpha.com/news/3269000-diana-containerships-beats-0_05-misses-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3269000-diana-containerships-beats-0_05-misses-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:37 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268997\" data-ts=\"1495456441\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLRX\" target=\"_blank\">BLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268997-biolinerx-advancing-toward-early-stage-study-of-lead-product-candidate-blminus-8040-and\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioLineRx advancing toward early-stage study of lead product candidate BL-8040 and Roche&#39;s Tecentriq in AML; shares up 6% premarket</a></h4><ul><li>Nano cap BioLineRx (NASDAQ:<a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a>) perks up<font color='green'> 6%</font>&nbsp;premarket on modest volume in response to its <a href=\"https://seekingalpha.com/pr/16839396-biolinerx-announces-regulatory-submission-phase-1b-trial-blminus-8040-combination\" target=\"_blank\">announcement </a>that it has filed regulatory applications seeking clearance to begin a Phase 1b clinical trial assessing the combination of BL-8040 and Roche's Tecentriq (atezolizumab) in patients with acute myeloid leukemia &#40;AML&#41;. The study, called BATTLE, should commence in H2.</li><li><a href=\"http://www.biolinerx.com/default.asp?pageid=98&amp;itemid=41\" target=\"_blank\">BL-8040</a>&nbsp;is a short peptide for the treatment of acute myeloid leukemia, solid tumors and certain hematological indications. It functions as a high-affinity antagonist for CXCR4, a chemokine receptor that is directly involved in tumor progression, angiogenesis, metastasis and cell survival. CXCR4 is over-expressed in more than 70% of human cancers and its expression often correlates with disease severity.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268997\" data-linked=\"BioLineRx advancing toward early-stage study of lead product candidate BL-8040 and Roche&#39;s Tecentriq in AML; shares up 6% premarket\" data-tweet=\"$BLRX - BioLineRx advancing toward early-stage study of lead product candidate BL-8040 and Roche&#39;s Tecentriq in AML; shares up 6% premarket https://seekingalpha.com/news/3268997-biolinerx-advancing-toward-early-stage-study-of-lead-product-candidate-blminus-8040-and?source=tweet\" data-url=\"https://seekingalpha.com/news/3268997-biolinerx-advancing-toward-early-stage-study-of-lead-product-candidate-blminus-8040-and\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:34 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268995\" data-ts=\"1495456317\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RMCF\" target=\"_blank\">RMCF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268995-on-rocky-mountain-chocolate-factorys-q4\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Rocky Mountain Chocolate Factory&#39;s Q4</a></h4><ul><li>Rocky Mountain Chocolate Factory (NASDAQ:<a href='https://seekingalpha.com/symbol/RMCF' title='Rocky Mountain Chocolate Factory, Inc.'>RMCF</a>) reports retail same-store sales fell 4% in <a href=\"https://seekingalpha.com/pr/16839561-rocky-mountain-chocolate-factory-inc-reports-operating-results-three-months-fiscal-year-ended\" target=\"_blank\">Q4</a>.</li><li>Total Factory sales dropped 6.3% to $7.26M due primarily to a 12.2 percent decrease in shipments of product to the Company's network of franchise and licensed retail locations.</li><li>Retail sales slipped 9.2% to $1.02M primarily due to the sale of certain Company-owned locations and the closure of an underperforming Company-owned location.</li><li>Royalties and marketing fees down 1.6% to $1.99M.</li><li>Adjusted EBITDA declined 25.1% to $1.64M.</li><li>Store count -22 Q/Q to 522.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268995\" data-linked=\"More on Rocky Mountain Chocolate Factory&#39;s Q4\" data-tweet=\"$RMCF - More on Rocky Mountain Chocolate Factory&#39;s Q4 https://seekingalpha.com/news/3268995-on-rocky-mountain-chocolate-factorys-q4?source=tweet\" data-url=\"https://seekingalpha.com/news/3268995-on-rocky-mountain-chocolate-factorys-q4\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268993\" data-ts=\"1495456041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QCOM\" target=\"_blank\">QCOM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268993-qualcommplus-1_7-after-j-p-morgan-upgrade-citing-nxp-semi-optimism\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qualcomm +1.7% after J.P. Morgan upgrade citing NXP Semi optimism</a></h4><ul>     <li>Qualcomm (NASDAQ:<a href='https://seekingalpha.com/symbol/QCOM' title='Qualcomm Inc.'>QCOM</a>)&nbsp;<font color='green'>+1.7%</font> premarket after J.P. Morgan <a href=\"http://www.marketwatch.com/story/qualcomms-stock-jumps-after-jp-morgan-upgrade-2017-05-22\" target=\"_blank\">upgrades</a> shares to Overweight from Neutral with a $68 price target, raised from $50, citing improved valuation and optimism over the upcoming closure of the NXP Semiconductors acquisition.</li><li>While more negative news from the <a href=\"https://seekingalpha.com/news/3268071-qualcomm-files-suit-apple-manufacturers\" target=\"_blank\">dispute with Apple</a> over royalty payments is likely, JPM analyst Rod Hall expects \"material fundamental upside\" from the closure of the NXP deal by the end of this year and sees the deal as highly accretive.</li><li>Hall also believes Apple ultimately will want to preserve its commercial relationship with QCOM.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268993\" data-linked=\"Qualcomm +1.7% after J.P. Morgan upgrade citing NXP Semi optimism\" data-tweet=\"$QCOM - Qualcomm +1.7% after J.P. Morgan upgrade citing NXP Semi optimism https://seekingalpha.com/news/3268993-qualcommplus-1_7-after-j-p-morgan-upgrade-citing-nxp-semi-optimism?source=tweet\" data-url=\"https://seekingalpha.com/news/3268993-qualcommplus-1_7-after-j-p-morgan-upgrade-citing-nxp-semi-optimism\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:27 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268989\" data-ts=\"1495455578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FINL\" target=\"_blank\">FINL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268989-monness-crespi-positive-on-finish-line\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Monness Crespi positive on Finish Line</a></h4><ul> <li>Monness Crespi Hardt upgrades Finish Line (NASDAQ:<a href='https://seekingalpha.com/symbol/FINL' title='The Finish Line, Inc.'>FINL</a>) are shares took a thrashing last week following weak results from Foot Locker.</li> <li>The investment firm <a href=\"https://www.benzinga.com/news/17/05/9497614/monness-crespi-hardt-upgrades-finish-line-to-buy\" target=\"_blank\">takes</a> FINL to Buy from Neutral and sets a price target of $17 to rep 23% upside potential.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3268796-shoe-stocks-pulled-foot-locker-results\" target=\"_blank\">Shoe stocks pulled down by Foot Locker results</a> (May 19)</li> <li>FINL <font color='green'>+1.44%</font> premarket to $14.07.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3268989\" data-linked=\"Monness Crespi positive on Finish Line\" data-tweet=\"$FINL - Monness Crespi positive on Finish Line https://seekingalpha.com/news/3268989-monness-crespi-positive-on-finish-line?source=tweet\" data-url=\"https://seekingalpha.com/news/3268989-monness-crespi-positive-on-finish-line\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:19 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268987\" data-ts=\"1495455326\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BX\" target=\"_blank\">BX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268987-blackstoneplus-5-on-40b-saudi-infrastructure-investment-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Blackstone +5% on $40B Saudi infrastructure investment deal</a></h4><ul>     <li>Blackstone (NYSE:<a href='https://seekingalpha.com/symbol/BX' title='The Blackstone Group L.P.'>BX</a>)&nbsp;<font color='green'>+5.3%</font> premarket after signing a memorandum of understanding with Saudi Arabia's PIF sovereign wealth fund to create a <a href=\"https://www.blackstone.com/media/press-releases/blackstone-to-launch-$40-billion-infrastructure-investment-vehicle-and-new-infrastructure-business\" target=\"_blank\">$40B vehicle to invest in infrastructure projects</a>, mainly in the U.S.</li>     <li>BX plans for $40B of equity commitments in the vehicle, with a $20B anchor investment from PIF and the  rest from other investors; through this equity plus debt financing, BX expects to invest in more than $100B of infrastructure projects.</li>     <li>The proposed venture was first announced during Pres.&nbsp;Trump's <a href=\"https://seekingalpha.com/news/3268923-deal-summary-saudi-arabia\" target=\"_blank\">weekend visit</a> to Saudi Arabia.</li><li>Citigroup <a href=\"https://www.streetinsider.com/Analyst+Comments/Citi+Upgrades+The+Blackstone+Group+%28BX%29+to+Buy+Amid+%2440B+Infrastructure+Fund/12929810.html\" target=\"_blank\">upgrades BX to Buy</a> from Neutral with a $40 price target in reaction to the news.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268987\" data-linked=\"Blackstone +5% on $40B Saudi infrastructure investment deal\" data-tweet=\"$BX - Blackstone +5% on $40B Saudi infrastructure investment deal https://seekingalpha.com/news/3268987-blackstoneplus-5-on-40b-saudi-infrastructure-investment-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3268987-blackstoneplus-5-on-40b-saudi-infrastructure-investment-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268985\" data-ts=\"1495455261\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CELG\" target=\"_blank\">CELG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268985-celgenes-ozanimod-successful-in-second-late-stage-ms-study-regulatory-submissions-on-tap-year\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celgene&#39;s ozanimod successful in second late-stage MS study, regulatory submissions on tap by year-end</a></h4><ul><li>Celgene (NASDAQ:<a href='https://seekingalpha.com/symbol/CELG' title='Celgene Corporation'>CELG</a>) is up a fraction premarket on the heels of its <a href=\"https://seekingalpha.com/pr/16839423-celgene-announces-positive-results-radiance-second-pivotal-phase-iii-trial-oral-ozanimod\" target=\"_blank\">announcement </a>of positive results from a second Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT02047734?term=rpc1063&amp;phase=2&amp;rank=5\" target=\"_blank\">RADIANCE</a>, assessing ozanimod (formerly RPC1063) for the treatment of relapsing multiple sclerosis &#40;RMS&#41;.</li><li>The study met the primary endpoint of reducing annualized relapse rate compared to Biogen's (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) <a href=\"https://www.avonex.com/?cid=ppc-ggl-gs-avonex-na-1-gs_avonex\" target=\"_blank\">Avonex </a>(interferon beta-1a).</li><li>The company reported successful results from its first Phase 3, SUNBEAM, in February.</li><li>Detailed results will be submitted for presentation at an upcoming medical conference. Global regulatory filings will commence by year-end.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3244410-celgenes-ozanimod-successful-late-stage-ms-study-shares-fraction-premarket\" target=\"_blank\">Celgene's ozanimod successful in late-stage MS study; shares up a fraction premarket</a> (Feb. 17)</li></ul><div class=\"tiny-share-widget\" data-id=\"3268985\" data-linked=\"Celgene&#39;s ozanimod successful in second late-stage MS study, regulatory submissions on tap by year-end\" data-tweet=\"$CELG $CELG $BIIB - Celgene&#39;s ozanimod successful in second late-stage MS study, regulatory submissions on tap by year-end https://seekingalpha.com/news/3268985-celgenes-ozanimod-successful-in-second-late-stage-ms-study-regulatory-submissions-on-tap-year?source=tweet\" data-url=\"https://seekingalpha.com/news/3268985-celgenes-ozanimod-successful-in-second-late-stage-ms-study-regulatory-submissions-on-tap-year\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268984\" data-ts=\"1495455116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RTN\" target=\"_blank\">RTN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268984-saudi-arms-deal-boosts-defense-stocks\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Saudi arms deal boosts defense stocks</a></h4><ul><li>It follows a $350B U.S-Saudi arms deal that was <a href=\"https://seekingalpha.com/news/3268911-u-s-saudis-seal-350b-weapons-deal\" target=\"_blank\">signed</a>  over the weekend during President Trump's visit to Riyadh.</li><li>Related tickers: <a href='https://seekingalpha.com/symbol/RTN' title='Raytheon Company'>RTN</a> <font color='green'>+3.6%</font>, <a href='https://seekingalpha.com/symbol/LMT' title='Lockheed Martin'>LMT</a> <font color='green'>+2.6%</font>, <a href='https://seekingalpha.com/symbol/GD' title='General Dynamics Corporation'>GD</a> <font color='green'>+2.1%</font>, <a href='https://seekingalpha.com/symbol/NOC' title='Northrop Grumman Corporation'>NOC</a> <font color='green'>+2%</font>, <a href='https://seekingalpha.com/symbol/BA' title='The Boeing Company'>BA</a> <font color='green'>+1.5%</font>, <a href='https://seekingalpha.com/symbol/HII' title='Huntington Ingalls Industries, Inc.'>HII</a> <font color='green'>+1%</font>, <a href='https://seekingalpha.com/symbol/UTX' title='United Technologies Corporation'>UTX</a> <font color='green'>+0.6%</font></li></ul><div class=\"tiny-share-widget\" data-id=\"3268984\" data-linked=\"Saudi arms deal boosts defense stocks\" data-tweet=\"$RTN $RTN $LMT - Saudi arms deal boosts defense stocks https://seekingalpha.com/news/3268984-saudi-arms-deal-boosts-defense-stocks?source=tweet\" data-url=\"https://seekingalpha.com/news/3268984-saudi-arms-deal-boosts-defense-stocks\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268976\" data-ts=\"1495454174\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ZOES\" target=\"_blank\">ZOES</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268976-baird-cautious-on-zoes-kitchen-ahead-of-earnings\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Baird cautious on Zoe&#39;s Kitchen ahead of earnings</a></h4><ul> <li>Baird <a href=\"https://www.briefing.com/Investor/PopupPages/ArticlePopup.aspx?ArticleId=UD20170522064931\" target=\"_blank\">lowers</a> its rating on Zoe's Kitchen (NYSE:<a href='https://seekingalpha.com/symbol/ZOES' title='Zoe&#39;s Kitchen'>ZOES</a>) to Neutral from Outperform.</li> <li>The investment firm drops its price target on the restaurant stock to $20 from $25.</li> <li>Zoe's Kitchen is due to report earnings on May 25.</li> <li>ZOES <font color='red'>-2.20%</font> premarket to $17.78.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268976\" data-linked=\"Baird cautious on Zoe&#39;s Kitchen ahead of earnings\" data-tweet=\"$ZOES - Baird cautious on Zoe&#39;s Kitchen ahead of earnings https://seekingalpha.com/news/3268976-baird-cautious-on-zoes-kitchen-ahead-of-earnings?source=tweet\" data-url=\"https://seekingalpha.com/news/3268976-baird-cautious-on-zoes-kitchen-ahead-of-earnings\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:56 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268970\" data-ts=\"1495453150\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NUTR\" target=\"_blank\">NUTR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268970-hggc-takes-nutraceutical-private-for-446m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">HGGC takes Nutraceutical private for $446M</a></h4><ul><li>Private equity outfit HGGC inks an <a href=\"https://seekingalpha.com/pr/16839366-nutraceutical-enters-definitive-agreement-acquired-hggc\" target=\"_blank\">agreement </a>to acquire Neutraceutical International (NASDAQ:<a href='https://seekingalpha.com/symbol/NUTR' title='Nutraceutical International Corporation'>NUTR</a>) for ~$446M, including debt. Under the terms of the deal, Nutraceutical shareholders will receive $41.80/share in cash, a 49% premium over Friday's close of $28.00.</li><li>The company will have a 60-day \"go-shop\" period during which it can solicit other offers. The transaction should close in H2.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268970\" data-linked=\"HGGC takes Nutraceutical private for $446M\" data-tweet=\"$NUTR - HGGC takes Nutraceutical private for $446M https://seekingalpha.com/news/3268970-hggc-takes-nutraceutical-private-for-446m?source=tweet\" data-url=\"https://seekingalpha.com/news/3268970-hggc-takes-nutraceutical-private-for-446m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268962\" data-ts=\"1495451811\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNC\" target=\"_blank\">GNC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268962-gnc-holdings-pops-after-nutraceutical-takeover\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GNC Holdings pops after Nutraceutical takeover</a></h4><ul> <li>Shares of GNC Holdings (NYSE:<a href='https://seekingalpha.com/symbol/GNC' title='GNC Holdings, Inc.'>GNC</a>) fly in premarket action after Nutraceutical is swallowed up by peer HGGC for $446M.</li> <li>GNC <font color='green'>+6.59%</font> premarket to $7.76.</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3268962\" data-linked=\"GNC Holdings pops after Nutraceutical takeover\" data-tweet=\"$GNC - GNC Holdings pops after Nutraceutical takeover https://seekingalpha.com/news/3268962-gnc-holdings-pops-after-nutraceutical-takeover?source=tweet\" data-url=\"https://seekingalpha.com/news/3268962-gnc-holdings-pops-after-nutraceutical-takeover\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:16 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>22&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268960\" data-ts=\"1495451666\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDUS\" target=\"_blank\">RDUS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268960-unexpected-cardiovascular-risk-amgen-and-ucbs-romosozumab-and-longer-timeline-for-potential-u\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Unexpected cardiovascular risk with Amgen and UCB&#39;s romosozumab and longer timeline for potential U.S. approval bodes well for Radius Health&#39;s Tymlos; shares ahead 18% premarket</a></h4><ul><li>Radius Health (NASDAQ:<a href='https://seekingalpha.com/symbol/RDUS' title='Radius Health, Inc.'>RDUS</a>) is up&nbsp;<font color='green'>18%</font>&nbsp;premarket on light volume after Amgen's announcement of late-stage results for osteoporosis candidate EVENITY (romosozumab) that included an unexpected cardiovascular safety signal.</li><li>The FDA recently approved (April) Radius' TYMLOS (abaloparatide) for the same population of high risk postmenopausal women. It carries no increased cardiovascular risk but its <a href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf\" target=\"_blank\">package insert</a> has a boxed warning about an increased risk of osteosarcoma.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3268953-amgens-ucbs-romosozumab-successful-late-stage-osteoporosis-study-cardiovascular-safety-signal\" target=\"_blank\">Amgen's and UCB's romosozumab successful in late-stage osteoporosis study but cardiovascular safety signal observed; Amgen down 2% premarket</a> (May 22)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3261375-fda-oks-radius-healths-osteoporosis-med-tymlos-shares-11-percent\" target=\"_blank\">FDA OKs Radius Health's osteoporosis med TYMLOS; shares up 11%</a> (April 28)</li></ul><div class=\"tiny-share-widget\" data-id=\"3268960\" data-linked=\"Unexpected cardiovascular risk with Amgen and UCB&#39;s romosozumab and longer timeline for potential U.S. approval bodes well for Radius Health&#39;s Tymlos; shares ahead 18% premarket\" data-tweet=\"$RDUS - Unexpected cardiovascular risk with Amgen and UCB&#39;s romosozumab and longer timeline for potential U.S. approval bodes well for Radius Health&#39;s Tymlos; shares ahead 18% premarket https://seekingalpha.com/news/3268960-unexpected-cardiovascular-risk-amgen-and-ucbs-romosozumab-and-longer-timeline-for-potential-u?source=tweet\" data-url=\"https://seekingalpha.com/news/3268960-unexpected-cardiovascular-risk-amgen-and-ucbs-romosozumab-and-longer-timeline-for-potential-u\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268961\" data-ts=\"1495451541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/F\" target=\"_blank\">F</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268961-ford-higher-after-ceo-shakeup\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ford higher after CEO shakeup</a></h4><ul> <li>Ford (NYSE:<a href='https://seekingalpha.com/symbol/F' title='Ford Motor Company'>F</a>) is <font color='green'>up 2.12%</font> in premarket trading to $11.10 after reports indicate that CEO Mark Fields will be replaced by Jim Hackett.</li><li>The company has scheduled a news conference in Detroit for 9:45 a.m. ET.</li>  <li>Shares of Ford are down 18% over the last 52 weeks.</li> <li>Previously: <a href=\"https://seekingalpha.com/news/3268925-fords-ceo-fields-shown-door\" target=\"_blank\">Ford's CEO Fields to be shown the door</a> (May 22)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3268961\" data-linked=\"Ford higher after CEO shakeup\" data-tweet=\"$F - Ford higher after CEO shakeup https://seekingalpha.com/news/3268961-ford-higher-after-ceo-shakeup?source=tweet\" data-url=\"https://seekingalpha.com/news/3268961-ford-higher-after-ceo-shakeup\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:12 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3268953\" data-ts=\"1495450698\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMGN\" target=\"_blank\">AMGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3268953-amgens-and-ucbs-romosozumab-successful-in-late-stage-osteoporosis-study-cardiovascular-safety\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Amgen&#39;s and UCB&#39;s romosozumab successful in late-stage osteoporosis study but cardiovascular safety signal observed; Amgen down 2% premarket</a></h4><ul><li>Amgen (NASDAQ:<a href='https://seekingalpha.com/symbol/AMGN' title='Amgen Inc.'>AMGN</a>) and development partner UCB (<a href='https://seekingalpha.com/symbol/UCBJF' title='UCB S.A.'>OTCPK:UCBJF</a>)(<a href='https://seekingalpha.com/symbol/UCBJY' title='UCB S.A. ADR'>OTCPK:UCBJY</a>) <a href=\"https://seekingalpha.com/pr/16839211-amgen-ucb-announce-top-line-phase-3-data-active-comparator-study-evenity-romosozumab\" target=\"_blank\">announce</a> positive results from a Phase 3 clinical trial, <a href=\"https://clinicaltrials.gov/ct2/show/NCT01631214?term=romosozumab&amp;rank=5\" target=\"_blank\">ARCH</a>, assessing EVENITY (romosozumab) for preventing fractures in postmenopausal women at high risk of fracture.</li><li>The study met both primary endpoints and the key secondary endpoint. The primary analysis showed treatment with EVENITY for 12 months followed by alendronate (Merck's Fosamax) significantly reduced the incidence of new fracture through 24 months, clinical fractures and non-vertebral fractures compared to alendronate alone.</li><li>A negative was a higher rate of serious cardiovascular adverse events observed (2.5%) in the EVENITY cohort compared to alendronate alone (1.9%).</li><li>Regulatory applications are currently under review in the U.S., Canada and Japan. Amgen has agreed with the FDA that data from ARCH should be considered in its review so approval will not happen this year. The marketing application in Europe is being prepared.</li><li>Romosozumab is a monoclonal antibody that inhibits a protein called <a href=\"https://en.wikipedia.org/wiki/Sclerostin\" target=\"_blank\">sclerostin </a>which is produced by bone cells and has anti-anabolic effects on bone formation.</li><li>Amgen and UCB have been collaborating on developing sclerostin-targeting antibodies since 2004.</li><li>Amgen is down&nbsp;<font color='red'>2%</font>&nbsp;premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3268953\" data-linked=\"Amgen&#39;s and UCB&#39;s romosozumab successful in late-stage osteoporosis study but cardiovascular safety signal observed; Amgen down 2% premarket\" data-tweet=\"$AMGN $AMGN $UCBJF - Amgen&#39;s and UCB&#39;s romosozumab successful in late-stage osteoporosis study but cardiovascular safety signal observed; Amgen down 2% premarket https://seekingalpha.com/news/3268953-amgens-and-ucbs-romosozumab-successful-in-late-stage-osteoporosis-study-cardiovascular-safety?source=tweet\" data-url=\"https://seekingalpha.com/news/3268953-amgens-and-ucbs-romosozumab-successful-in-late-stage-osteoporosis-study-cardiovascular-safety\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:58 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>16&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li>","count":57,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}